{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:51:59Z","timestamp":1794466319403,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1739,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NORD grant"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objective<\/jats:title>\n                    <jats:p>Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug-eluting bead transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short-term CT assessment would demonstrate stable disease or partial response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Client-owned dogs (n = 16) with nonresectable HC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, single-arm clinical trial. Drug-eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12\u2009weeks after initial treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Drug-eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8\/13; 62%) was the most common outcome followed by partial response (3\/13; 23%) and progressive disease (2\/13; 15%) with a median of 74\u2009days (range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7\/27 (26%) treatments. Major complications occurred after 3\/27 (11%) treatments: hepatic abscess\/septicemia (2) and cholecystitis\/death (1), resulting in treatment-induced death after 2\/27 (7%) treatments. Median survival time after treatment was 337\u2009days (range, 22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126\u2009days; range, 46-337) than those dogs without prior history of weight loss (582\u2009days; range, 22-1061).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drug-eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16109","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T21:46:24Z","timestamp":1620337584000},"page":"1487-1495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-9972","authenticated-orcid":false,"given":"Cleo P.","family":"Rogatko","sequence":"first","affiliation":[{"name":"The Animal Medical Center , New York, New York,","place":["USA"]},{"name":"Veterinary Surgical Centers , Vienna, Virginia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-9962","authenticated-orcid":false,"given":"Chick","family":"Weisse","sequence":"additional","affiliation":[{"name":"The Animal Medical Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-573X","authenticated-orcid":false,"given":"Tobias","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Royal (Dick) School of Veterinary Studies, The University of Edinburgh , Roslin,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson C.","family":"Berent","sequence":"additional","affiliation":[{"name":"The Animal Medical Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio A.","family":"Diniz","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center , Los Angeles, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"2026020303071992600_jvim16109-bib-0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/030098588101800402","article-title":"Canine hepatocellular carcinoma","volume":"18","author":"Patnaik","year":"1981","journal-title":"Vet Pathol"},{"key":"2026020303071992600_jvim16109-bib-0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/030098588001700504","article-title":"Canine hepatic neoplasms: a clinicopathologic study","volume":"17","author":"Patnaik","year":"1980","journal-title":"Vet Pathol"},{"key":"2026020303071992600_jvim16109-bib-0003","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2460\/javma.2004.225.1225","article-title":"Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002)","volume":"225","author":"Liptak","year":"2004","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303071992600_jvim16109-bib-0004","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.tvjl.2013.05.027","article-title":"Classification of primary hepatic tumours in the dog","volume":"197","author":"van Sprundel","year":"2013","journal-title":"Vet J"},{"key":"2026020303071992600_jvim16109-bib-0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2460\/javma.1976.169.04.429","article-title":"Bile duct carcinoma in dogs","volume":"169","author":"Strafuss","year":"1976","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303071992600_jvim16109-bib-0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/030098588101800403","article-title":"Canine bile duct carcinoma","volume":"18","author":"Patnaik","year":"1981","journal-title":"Vet Pathol"},{"key":"2026020303071992600_jvim16109-bib-0007","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1354\/vp.42-2-140","article-title":"Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study","volume":"42","author":"Patnaik","year":"2005","journal-title":"Vet Pathol"},{"key":"2026020303071992600_jvim16109-bib-0008","doi-asserted-by":"crossref","DOI":"10.5326\/JAAHA-MS-6887","article-title":"Primary hepatic neuroendocrine carcinoma treated with doxorubicin and cyclophosphamide in a dog","volume":"55","author":"Morgan","year":"2019","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020303071992600_jvim16109-bib-0009","first-page":"598","article-title":"Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors","volume":"56","author":"Kinsey","year":"2015","journal-title":"Can Vet J"},{"key":"2026020303071992600_jvim16109-bib-0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/00480169.2017.1319304","article-title":"Impact of surgical margins on survival of 37 dogs with massive hepatocellular carcinoma","volume":"65","author":"Matsuyama","year":"2017","journal-title":"N Z Vet J"},{"key":"2026020303071992600_jvim16109-bib-0011","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/vsu.13164","article-title":"Outcomes and prognostic variables associated with central division hepatic lobectomies: 61 dogs","volume":"48","author":"Linden","year":"2019","journal-title":"Vet Surg"},{"key":"2026020303071992600_jvim16109-bib-0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"2026020303071992600_jvim16109-bib-0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1148\/radiol.11081489","article-title":"Transcatheter intraarterial therapies: rationale and overview","volume":"259","author":"Lewandowski","year":"2011","journal-title":"Radiology"},{"key":"2026020303071992600_jvim16109-bib-0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00001622-199901000-00009","article-title":"Embolization and chemoembolization therapy for neuroendocrine tumors","volume":"11","author":"Venook","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"2026020303071992600_jvim16109-bib-0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-9966-33-43","article-title":"Hepatic arterial embolization in patients with neuroendocrine tumors","volume":"33","author":"Del Prete","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"2026020303071992600_jvim16109-bib-0016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1757-1626-1-314","article-title":"Primary hepatic carcinoid; a diagnostic dilemma: a case report","volume":"1","author":"Touloumis","year":"2008","journal-title":"Cases J"},{"key":"2026020303071992600_jvim16109-bib-0017","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00270-019-02344-0","article-title":"Chemoembolization with degradable starch microspheres for treatment of patients with primary or recurrent unresectable, locally advanced intrahepatic cholangiocarcinoma: a pilot study","volume":"42","author":"Goerg","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0018","first-page":"123","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy","volume":"2","author":"Jang","year":"2015","journal-title":"J Hepatocell Carcinoma"},{"key":"2026020303071992600_jvim16109-bib-0019","first-page":"3892","article-title":"Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"2026020303071992600_jvim16109-bib-0020","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"2026020303071992600_jvim16109-bib-0021","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"2026020303071992600_jvim16109-bib-0022","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy","volume":"24","author":"Kuhlmann","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026020303071992600_jvim16109-bib-0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00270-007-9186-3","article-title":"Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases","volume":"31","author":"Kamat","year":"2008","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0024","first-page":"746","article-title":"Primary hepatic carcinoid tumor: case report and review of 53 cases","volume":"7","author":"Iwao","year":"2001","journal-title":"Med Sci Monit"},{"key":"2026020303071992600_jvim16109-bib-0025","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jso.21522","article-title":"Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)","volume":"101","author":"Dhanasekaran","year":"2010","journal-title":"J Surg Oncol"},{"key":"2026020303071992600_jvim16109-bib-0026","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jvir.2010.04.018","article-title":"The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma","volume":"21","author":"Dhanasekaran","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"2026020303071992600_jvim16109-bib-0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0028","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","article-title":"Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"22","author":"Sacco","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"2026020303071992600_jvim16109-bib-0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5009\/gnl.2013.7.1.89","article-title":"DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study","volume":"7","author":"Song","year":"2013","journal-title":"Gut Liver"},{"key":"2026020303071992600_jvim16109-bib-0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00270-013-0654-7","article-title":"Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma","volume":"37","author":"Kalva","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/vsu.12768","article-title":"Total prostatectomy as a treatment for prostatic carcinoma in 25 dogs","volume":"47","author":"Bennett","year":"2018","journal-title":"Vet Surg"},{"key":"2026020303071992600_jvim16109-bib-0032","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/kjhep.2011.17.1.51","article-title":"Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose","volume":"17","author":"Martin","year":"2011","journal-title":"Korean J Hepatol"},{"key":"2026020303071992600_jvim16109-bib-0033","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tvjl.2015.03.027","article-title":"Veterinary interventional oncology: from concept to clinic","volume":"205","author":"Weisse","year":"2015","journal-title":"Vet J"},{"key":"2026020303071992600_jvim16109-bib-0034","doi-asserted-by":"crossref","DOI":"10.2460\/javma.2002.221.1430","article-title":"Percutaneous arterial embolization and chemoembolization for treatment of benign and malignant tumors in three dogs and a goat","volume":"221","author":"Weisse","year":"2002","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303071992600_jvim16109-bib-0035","doi-asserted-by":"crossref","DOI":"10.1002\/9781118910924","article-title":"Veterinary Image-Guided Interventions","author":"Weisse","year":"2015"},{"key":"2026020303071992600_jvim16109-bib-0036","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.2252011604","article-title":"CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques\u2014initial observations","volume":"225","author":"Prasad","year":"2002","journal-title":"Radiology"},{"key":"2026020303071992600_jvim16109-bib-0037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2026020303071992600_jvim16109-bib-0038","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026020303071992600_jvim16109-bib-0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048372","article-title":"Tumor volume as an alternative response measurement for imatinib treated GIST patients","volume":"7","author":"Schiavon","year":"2012","journal-title":"PLoS One"},{"key":"2026020303071992600_jvim16109-bib-0040","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ejrad.2015.12.019","article-title":"Comparison of CT volumetric measurement with RECIST response in patients with lung cancer","volume":"85","author":"Hayes","year":"2016","journal-title":"Eur J Radiol"},{"key":"2026020303071992600_jvim16109-bib-0041","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"2026020303071992600_jvim16109-bib-0042","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5829.2011.00262.x","article-title":"Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas","volume":"9","author":"Elpiner","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"2026020303071992600_jvim16109-bib-0043","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/hpb.12487","article-title":"Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma","volume":"17","author":"Mason","year":"2015","journal-title":"HPB"},{"key":"2026020303071992600_jvim16109-bib-0044","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00270-010-0044-3","article-title":"Safety profile of sequential transcatheter chemoembolization with DC bead\u2122: results of 237 hepatocellular carcinoma (HCC) patients","volume":"34","author":"Malagari","year":"2011","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00330-016-4445-9","article-title":"Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization","volume":"27","author":"Gorodetski","year":"2017","journal-title":"Eur Radiol"},{"key":"2026020303071992600_jvim16109-bib-0046","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00270-018-1989-x","article-title":"Minimal risk of biliary tract complications, including hepatic abscess, after transarterial embolization for hepatocellular carcinoma using concentrated antibiotics mixed with particles","volume":"41","author":"Wang","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026020303071992600_jvim16109-bib-0047","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004836-200105000-00013","article-title":"Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"32","author":"Kim","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"2026020303071992600_jvim16109-bib-0048","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005606","article-title":"The incidence and outcome of major complication following conventional TAE\/TACE for hepatocellular carcinoma","volume":"95","author":"Tu","year":"2016","journal-title":"Medicine"},{"key":"2026020303071992600_jvim16109-bib-0049","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1365-2168.1998.00664.x","article-title":"Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization","volume":"85","author":"Liu","year":"1998","journal-title":"Br J Surg"},{"key":"2026020303071992600_jvim16109-bib-0050","article-title":"Rupture of hepatocellular carcinoma after transarterial chemoembolization followed by massive gastric bleeding","volume":"2018","author":"Nishida","year":"2018","journal-title":"Case Rep Hepatol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/3\/1487\/66651882\/jvim16109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/3\/1487\/66651882\/jvim16109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:07:40Z","timestamp":1770106060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/3\/1487\/8446962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16109","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"2020-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}